Your browser is no longer supported. Please, upgrade your browser.
Settings
GLMD Galmed Pharmaceuticals Ltd. daily Stock Chart
GLMD [NASD]
Galmed Pharmaceuticals Ltd.
Index- P/E- EPS (ttm)-0.67 Insider Own21.61% Shs Outstand21.15M Perf Week-0.58%
Market Cap179.78M Forward P/E- EPS next Y-1.00 Insider Trans0.00% Shs Float16.46M Perf Month-19.43%
Income-9.80M PEG- EPS next Q-0.14 Inst Own38.20% Short Float1.07% Perf Quarter-32.75%
Sales2.30M P/S78.16 EPS this Y33.90% Inst Trans-11.93% Short Ratio1.28 Perf Half Y25.00%
Book/sh4.33 P/B1.96 EPS next Y- ROA-17.50% Target Price34.14 Perf Year4.42%
Cash/sh4.36 P/C1.95 EPS next 5Y- ROE-18.60% 52W Range3.61 - 27.06 Perf YTD-7.10%
Dividend- P/FCF- EPS past 5Y-26.10% ROI-78.30% 52W High-68.59% Beta2.87
Dividend %- Quick Ratio43.30 Sales past 5Y- Gross Margin- 52W Low135.46% ATR0.69
Employees17 Current Ratio43.30 Sales Q/Q400.00% Oper. Margin- RSI (14)39.79 Volatility5.39% 7.60%
OptionableYes Debt/Eq0.00 EPS Q/Q79.80% Profit Margin- Rel Volume0.62 Prev Close8.56
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume137.39K Price8.50
Recom1.90 SMA20-5.20% SMA50-19.62% SMA200-13.88% Volume84,881 Change-0.70%
Aug-02-18Reiterated Maxim Group Buy $30 → $27
Jul-13-18Initiated Stifel Buy $35
Jul-12-18Initiated Cantor Fitzgerald Overweight $59
Jun-12-18Reiterated H.C. Wainwright Buy $24 → $43
Mar-15-18Upgrade Maxim Group Hold → Buy $14
Feb-14-18Downgrade Maxim Group Buy → Hold
Feb-12-18Reiterated H.C. Wainwright Buy $18 → $24
Nov-15-17Initiated ROTH Capital Buy $32
Aug-08-17Reiterated H.C. Wainwright Buy $12 → $18
Jul-31-17Reiterated Maxim Group Buy $9 → $14
Aug-01-16Reiterated Maxim Group Buy $24 → $9
Jul-06-16Resumed ROTH Capital Buy $6
Mar-28-16Resumed H.C. Wainwright Buy $22
Jun-23-15Initiated H.C. Wainwright Buy $21
May-06-15Initiated Sun Trust Rbsn Humphrey Buy $20
Apr-15-15Initiated ROTH Capital Buy $20
Sep-24-14Reiterated MLV & Co Buy $19 → $24
May-09-14Initiated MLV & Co Buy $19
Apr-23-14Initiated Maxim Group Buy $24
Nov-20-18 08:45AM  Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher Zacks -5.48%
Nov-14-18 07:50AM  Recent Analysis Shows COUPA SOFTWARE, Galmed Pharmaceuticals, Sunworks, Murphy, Diversicare Healthcare Services, and Pro-Dex Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-13-18 11:30AM  Phase 2 Data for Galmed Pharmaceutical's Aramchol in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018 PR Newswire -7.01%
04:02AM  Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-05-18 08:45AM  Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.37%
07:39AM  Galmed Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results PR Newswire
Oct-31-18 03:38PM  Nantahala Capital Managements Returns, AUM, and Holdings Insider Monkey
Oct-29-18 08:30AM  Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5 PR Newswire
Oct-12-18 03:21PM  Who Really Owns Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)? Simply Wall St.
Oct-02-18 08:39AM  Galmed Pharmaceuticals Announces a Late-Breaking Abstract on Aramchol to be Presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® PR Newswire +5.47%
Sep-27-18 08:00AM  Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference PR Newswire
Aug-02-18 05:40PM  Medical-Drugs Stock Outlook: No Respite from Near-Term Pain Zacks
10:55AM  Galmed Pharmaceuticals (GLMD) Reports Q2 Loss Zacks
09:51AM  Galmed Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results PR Newswire
Jul-26-18 08:30AM  Galmed Pharmaceuticals to Report Second Quarter 2018 Financial Results and Provide Business Update on Thursday, August 2 PR Newswire
Jul-20-18 11:42AM  What's in Store for Universal Health's (UHS) Q2 Earnings? Zacks
11:26AM  What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings? Zacks
Jul-13-18 07:02PM  Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week Motley Fool +19.34%
10:49AM  Galmed Notches Second Bullish Rating On Aramchol Opportunity Benzinga
08:00AM  Today's Research Reports on Stocks to Watch: Galmed Pharmaceuticals and Zogenix ACCESSWIRE
Jul-12-18 12:11PM  Cantor Fitzgerald Makes An Uber-Bullish Call On Galmed Pharmaceuticals Benzinga +21.04%
08:00AM  Today's Research Reports on Trending Tickers: Galmed Pharmaceuticals and Akcea Therapeutics ACCESSWIRE
Jun-26-18 07:06AM  This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It Motley Fool
Jun-25-18 07:30AM  Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock ACCESSWIRE
Jun-20-18 08:36AM  Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading Benzinga -9.43%
Jun-19-18 09:37PM  Galmed Pharmaceuticals Ltd. Announces Pricing of Public Offering of Ordinary Shares PR Newswire +5.23%
Jun-18-18 06:30AM  Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares PR Newswire -9.09%
Jun-16-18 07:18AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-15-18 09:27AM  Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals Zacks
08:07AM  3 NASH Stocks That Could Soar in the Second Half of 2018 Motley Fool
07:40AM  Hacking the Human Brain: This Unknown Stock (With 1 Very Prominent Shareholder) Could Change The Game & Make Shareholders Unheard of Returns ACCESSWIRE
Jun-14-18 10:30AM  Are These Red-Hot NASH Stocks Still a Buy? Motley Fool -10.58%
09:23AM  NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
Jun-13-18 09:43AM  Galmed (GLMD) Soars on Positive NASH Data on Aramchol Zacks
08:15AM  Comprehensive Research Report, Galmed Pharmaceuticals Soars on Clinical Trial Results in Liver Disease Study ACCESSWIRE
08:00AM  Todays Research Reports on Stocks to Watch: Sage Therapeutics and Galmed Pharmaceuticals ACCESSWIRE
Jun-12-18 12:37PM  Why Galmed Pharmaceuticals Ltd Stock Is Going Gangbusters Today InvestorPlace +151.29%
11:23AM  Galmed's 200% Jump Leads Biotechs Higher Barrons.com
10:37AM  Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today Motley Fool
08:47AM  Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate Benzinga
08:36AM  Galmed Pharmaceuticals' stock rockets 161% after trial results support FDA marketing application MarketWatch
08:15AM  Israeli company Galmed gets positive trial results for liver drug Reuters
07:00AM  Galmed's 600 mg Aramchol Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study PR Newswire
Jun-11-18 04:30PM  Galmed Pharmaceuticals to Host Conference Call to Discuss Top-Line, 52-Week Results from the Global Phase 2b ARREST Study PR Newswire
May-14-18 10:11AM  Whats Ahead For Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)? Simply Wall St.
May-11-18 05:31PM  What You Must Know About Galmed Pharmaceuticals Ltds (NASDAQ:GLMD) Market Risks Simply Wall St.
May-09-18 07:21AM  Galmed Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results PR Newswire
May-02-18 08:18PM  Has Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Improved Earnings Growth In Recent Times? Simply Wall St.
May-01-18 08:00AM  Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9 PR Newswire
Apr-20-18 05:06PM  What Are Analysts Expecting From Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Over The Next Few Years? Simply Wall St.
Apr-16-18 07:00AM  Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol for NASH PR Newswire
Apr-11-18 08:00AM  InMed Announces Appointment of Joshua Blacher as Chief Business Officer CNW Group
Apr-03-18 07:00AM  Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering PR Newswire +15.08%
Mar-27-18 07:00AM  Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL PR Newswire -12.63%
Mar-15-18 01:12PM  Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade Benzinga +6.95%
Mar-13-18 07:30AM  Galmed Pharmaceuticals reports 4Q loss Associated Press
07:05AM  Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update PR Newswire
06:30AM  Galmed Pharmaceuticals Ltd. to Host Earnings Call ACCESSWIRE
Mar-05-18 07:00AM  Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13 PR Newswire
Mar-02-18 07:00AM  Galmed Pharmaceuticals to Participate in Investor Conferences in March PR Newswire
Feb-28-18 07:15PM  Galmed Pharmaceuticals Ltds (NASDAQ:GLMD) Path To Profitability Simply Wall St.
Feb-14-18 09:15AM  Galmed Pharma's stock loses more than half its value after drug trial misses endpoint MarketWatch -42.39%
07:00AM  Galmed Announces ARRIVE Study Data PR Newswire
Feb-08-18 07:00AM  Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire
Feb-07-18 09:08AM  Galmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits PR Newswire
Jan-02-18 07:00AM  Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017 PR Newswire
Dec-26-17 05:08PM  7 Stocks Moving In Tuesday's After-Hours Session Benzinga
Dec-18-17 08:15PM  Galmed Pharmaceuticals Ltd (NASDAQ:GLMD): Financial Strength Analysis Simply Wall St.
Nov-29-17 08:21AM  Galmed Pharmaceuticals Ltd. :GLMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 07:00AM  Galmed Pharmaceuticals to Present at HEP DART 2017 Meeting PR Newswire
Nov-24-17 01:35PM  Should You Buy Galmed Pharmaceuticals Ltd (GLMD) At $8.03? Simply Wall St.
Nov-09-17 07:43AM  Galmed Pharmaceuticals reports 3Q loss Associated Press
07:00AM  Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update PR Newswire
06:50AM  Galmed Pharmaceuticals Ltd. to Host Earnings Call ACCESSWIRE
Nov-07-17 07:00AM  Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference PR Newswire
Nov-01-17 07:00AM  Galmed Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 9th PR Newswire
Oct-19-17 07:00AM  Galmed Pharmaceuticals to Host Key Opinion Leader Meeting on Non-Alcoholic Steato-Hepatitis (NASH) PR Newswire
Oct-05-17 08:00AM  Galmed Pharmaceuticals Announces Publication of Data on Aramchol Mechanism of Action in Hepatology Communications. Data Will Also Be Presented at AASLD PR Newswire
Sep-05-17 08:53AM  3 Reasons Why Galmed Pharmaceuticals (GLMD) is a Great Momentum Stock Zacks
Aug-03-17 04:51PM  Galmed Pharmaceuticals Announces Pricing of Offering of Ordinary Shares to Existing Investors and Members of the Board of Directors PR Newswire
Jul-31-17 11:01PM  Galmed Pharmaceuticals reports 2Q loss Associated Press -9.50%
06:00AM  Galmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update PR Newswire
Jul-25-17 08:20AM  Galmed Pharmaceuticals (GLMD) Catches Eye: Stock Gains 15.7% Zacks
Jul-24-17 08:30AM  Galmed Pharmaceuticals Second Quarter 2017 Conference Call and Webcast Scheduled for Monday, July 31, 2017 PR Newswire +15.70%
Jun-08-17 07:00AM  Galmed Pharmaceuticals Announces the Election of Dr. Carol L. Brosgart as a New Member of the Board of Directors PR Newswire
May-15-17 08:52AM  Galmed Pharmaceuticals reports 1Q loss Associated Press
08:00AM  Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results PR Newswire
May-08-17 08:30AM  Galmed Pharmaceuticals First Quarter 2017 Conference Call and Webcast Scheduled for Monday, May 15th, 2017 PR Newswire
Apr-05-17 08:00AM  Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol has a Potential Direct Effect on Liver Fibrosis PR Newswire
08:00AM  Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol has a Potential Direct Effect on Liver Fibrosis
Mar-28-17 01:04PM  GALMED PHARMACEUTICALS LTD. Financials
Mar-23-17 07:52AM  Galmed Pharmaceuticals reports 4Q loss Associated Press
07:52AM  Galmed Pharmaceuticals reports 4Q loss
07:30AM  Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results PR Newswire
Mar-16-17 08:30AM  Galmed Pharmaceuticals Fourth Quarter 2016 Conference Call and Webcast Scheduled for Thursday, March 23rd, 2017 PR Newswire
Feb-24-17 01:21PM  NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 at Forbes
Jan-09-17 08:00AM  Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study PR Newswire
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.